Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer
First approved PARP inhibitor to demonstrate clinically meaningful benefits in combination with a new hormonal agent. Lynparza in combination with abiraterone extended median radiographic progression-free survival benefit beyond two years in this setting.AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men for whom chemotherapy is not clinically indicated. This approval by the European Commission was based on